๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

โœ Scribed by Seung Tae Lee; Joon Ho Jang; Hyung Chan Suh; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
97 KB
Volume
68
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
โœ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 89 KB ๐Ÿ‘ 2 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

FLAG (fludarabine, high-dose cytarabine,
FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children
โœ McCarthy, A.J.; Pitcher, L.A.; Hann, I.M.; Oakhill, A. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 63 KB ๐Ÿ‘ 2 views

Background. The treatment of relapsed and refractory leukemia in children remains a challenge. The morbidity of further chemotherapy is considerable, as most patients have already been exposed to intensive multiagent chemotherapy. The FLAG (fludarabine, high-dose cytarabine, and G-CSF) regimen is as

Letter to the Editor:FLAG (fludarabine,
Letter to the Editor:FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children
โœ Sarper, Nazan; Yalman, Nevin ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 41 KB ๐Ÿ‘ 2 views

## FLAG (Fludarabine, High-Dose Cytarabine and G-CSF) for Refractory and High-Risk Relapsed Acute Leukemia in Children We have read with interest the report about FLAG therapy in childhood acute leukemia by McCarthy et al. [1]. We want to add our experience with IDA-FLAG in poor-risk childhood leuk